| External factors: | 3-deazaneplanocin A |
| Aging type: | Accelerate |
| Aging characteristic: |
| Category: | Chemical compounds |
| Phenotype: | Aging |
| Experiment: | SA-β-gal activity assay//Cell morphological analysis |
| Description: | Senescence-like characteristics of HepG2 cells upon 5.0?μmol/L DZNep. (a) On day 3, the cells appeared normal in morphology; on day 6, the cells displayed senescence-like morphologies and positive SA-β-gal staining in green (observed at magnification of 400×). |
| Regulatory pathway: | p53-p21 |
| R-EF-Pathway: | Activation |
| Official symbol(s): | TP53-CDKN1A |
| Pathway experiment: | Western blot |
| Pathway description: | p53 activation and DDR caused by 5.0?μmol/L DZNep. Expression of p53 protein elevated after 3-day treatment.(b) Doxorubicin strongly induced p53 stabilization and nuclearization after 6?h, while DZNep causes p53 accumulation gradually until 72?h.mRNA expression of checkpoint inhibitors (p16, p21) upon DZNep treatment for 8 and 72?h. (c) Protein expression of checkpoint inhibitors (p16, p21) increased upon DZNep treatment on day 3. Quantification of the protein blot was performed by Image-Pro Plus (v6.0). transient activation of p53 in G2/M phase is sufficient to induce senescence together with p21 induction. |
Annotation: